BioMarin Pharmaceutical is acquiring Amicus Therapeutics for approximately $4.8 billion. The acquisition is expected to close in the second quarter of 2026. BioMarin is thus expanding its portfolio in the field of rare diseases to include Galafold for the treatment of Fabry disease and Pombiliti + Opfolda, an enzyme replacement therapy for Pompe disease.
Amicus also has U.S. rights to DMX-200, a potential first-in-class investigational small molecule for the treatment of focal segmental glomerulosclerosis (FSGS), a rare and fatal kidney disease in Phase 3 development.
The transaction is expected to have an immediate impact on sales and to increase earnings within 12 months. This is subject to regulatory clearances, approval by the stockholders of Amicus and other customary closing conditions.
Amicus has assured us that patients currently receiving and those new to Amicus’ medicines will continue to have uninterrupted access.
Source: Press release